Prostate Cancer

Phase I Trial Targets Monoclonal Antibody to Prostate-Specific Membrane Antigen

Published in Cancer Weekly, September 19th, 2000

Results from a Phase I clinical trial of a monoclonal antibody (MAb) targeting the extracellular domain of prostate specific membrane antigen (PSMAext) in patients with hormone-independent prostate cancer are very encouraging, report researchers.

"MAbs are currently approved for in vivo diagnosis and treatment of multiple diseases and have significant potential in the management of prostate cancer (Pca)," stated Neil H. Bander and colleagues from Weill Medical College of Cornell University, New York. "Prostascint, a MAb approved for Pca imaging, binds an intracellular epitope of PSMA and, as a result, does not bind to viable cells. Successful imaging of a given tumor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-09-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry